← TrialMatch
HomeTrials

Prebiotics and the Management of Hyperuricemia

Hyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel theraputic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanis

Condition(s)Subjects With Hyperuricemia
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryHyperuricemia is a major risk factor for many chronic diesease. Recently, gut mcirobiota has been identified as a novel theraputic target for hyperuricemia. Both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. This trial aims to examine its protective effects and potential mechanisms in clinical trials.
Who can participateInclusion Criteria: * Local residents aged between 18-80 years old; * Stable weight (\<5% weight change over the past 3 months); * Fsating uric acid \> 420 umol/L for male and \> 360 umol/L for female on two different days; * Not taking uric acid lowering drugs or have stopped taking uric acid lowering drugs for over 4 weeks at the time of recruitment; * Absence of any diet or medication that might interfere with uric acid metabolims or gut microbiota, especially antibiotics, prebiotics or probiotics at the least 4 weeks before recruitment Exclusion Criteria: * Acute illness or evidence of any acute or chronic inflammatroy of infective diseases; * Participation in regular diet program more than 2 times per week in the lastest 3 months prior to recruitment; * Mental illness rendering them u
Ages18 Years to 80 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorSun Yat-sen University
LocationsGuangzhou, Guangdong, China; Guangzhou, Guangdong, China
Start date2024-05-15
NCT IDNCT06420401
Official listinghttps://clinicaltrials.gov/study/NCT06420401

🔍 Search all trials →